AASLD: American Association for the Study of Liver Diseases
Home | Contact Us | Log In/Out
About Us | JoinPublic Policy | Patients | Giving to AASLD | Career Center | News | Worksites | Related Societies
 

Clinical Research Single Topic Conference 
|

Clinical Research Single Topic Conference
Acetaminophen Toxicity
Saturday June 9 - Sunday June 10, 2012
Emory Conference Center Hotel – Atlanta, GA 

Course Directors
Richard C. Dart, MD, PhD, Paul B. Watkins, MD, and Julia Wendon, MbChB, FRCP

Course Coordinator: Eric Lavonas, MD, FACEP, FACMT

Description
Acetaminophen is both the most commonly consumed medication and the most common cause of drug-induced acute liver failure (ALF) in the developed world. Recent advances in understanding of the mechanisms underlying acetaminophen liver injury have important therapeutic implications. This 1.5-day seminar will explore the current understanding of acetaminophen toxicity, from bench to bedside, with the goal of defining better ways to prevent, treat, and rescue patients from severe acetaminophen toxicity.

The course begins on Saturday afternoon with a combined session with the Basic Science Single Topic Conference on Mitochondria in Liver Disease, and continues to explore our deepening understanding of the molecular events that manifest themselves as acetaminophen-induced acute liver injury. Sunday's clinical lectures explore the state of the art in the prevention and treatment of severe acetaminophen poisoning, including treatment strategies that are just over the translational sciences horizon.

This course is designed to be interactive. The Course Directors have chosen speakers whose cutting-edge research is shaping the therapies of tomorrow. Lectures will be highly focused, with ample opportunity to ask questions and interact with the speakers and other course participants.

Goals and Objectives

  • Describe the current state of knowledge about the mechanisms of acetaminophen toxicity, with particular attention to recent advances in molecular science
  • Understand and be able to apply advanced techniques in the diagnosis and management of acetaminophen-induced liver injury
  • Understand the evidence underlying current strategies to prevent unintentional acetaminophen-induced liver injury

Call for Abstracts
We are no longer accepting abstract submissions.

 

 Registration

 Basic Research STC

Gain a deeper understanding of the science underlying mitochondrial toxicity. Register for both the Clinical and Basic STC and save $100.

 Important Documents

 Conference Center Housing

Reserve your room at the Emory Conference Center Hotel online or call 800-933-6679. Use "AASLD" for the group code.

 ‭(Hidden)‬ Custom List View Classes

 Saturday, June 9, 2012

SessionFilterPresenterFilter
Session I: Understanding Acetaminophen Toxicity: From Bench to Bedside
1:00 pm
Welcome and Introductions
Course Directors
Session IA: Mitochondrial Toxicity in Acetaminophen Poisoning (Joint Session with the Basic Research Conference)
Moderators: John J. Lemasters MD, PhD and Paul B. Watkins, MD
1:10 pm
Mitochondrial Reactive Oxygen and Nitrogen Species in Acetaminophen Hepatotoxicity
Jack A. Hinson, PhD
1:30 pm
Discussion
1:40 pm
Signal Transduction in Hepatotoxicity
Neil Kaplowitz, MD
2:00 pm
Discussion
2:10 pm
The Role of Mitochondria in Injury and Repair from Acetaminophen Poisoning
Hartmut W. Jaeschke, PhD
2:30 pm
Discussion
2:40 pm
Break
Session IB: The Cellular Processes of Acetaminophen-Induced Liver Injury
Moderators: Hartmut W. Jaeschke, PhD and Eric Lavonas, MD
 
3:00 pm
Second Hit: The Immune Response in Acetaminophen Poisoning
Wajahat Z. Mehal, MD
3:20 pm
Discussion
3:30 pm
Metabolic Activation and Secondary Toxicants: Beyond NAPQI
B. Kevin Park, PhD
3:50 pm
Discussion
4:00 pm
What Are the Cells Up To? Identification of Human Biomarkers of Hepatotoxicity Through Transcriptomics
Richard S. Paules, PhD
4:20 pm
Discussion
4:30 pm
Novel Biomarker Discovery in Healthy Volunteers and Patients with Acetaminophen Toxicity
Paul B. Watkins, MD
4:50 pm
Discussion
5:00 pm
Insights into the Management of Acetaminophen Poisoning from DILIsym – An In Silico Model of the Liver
Brett A. Howell, PhD
5:20 pm
Discussion
5:30 pm
Poster Session
7:00 pm
Dinner

 Sunday, June 10, 2012

SessionFilterPresenterFilter
Session II: Therapeutic Advances and Treatment Modalities on the Horizon
Session IIA: Advances in Critical Care
Moderators: Kennon Heard, MD and Neil Kaplowitz, MD
8:30 am
Critical Care Management: The Evolving State of the Art
Julia Wendon, MbChB, FRCP
8:50 am
Discussion
9:00 am
Neutrophil and Monocyte Involvement in Inflammation and Sepsis
Kenneth J. Simpson, MD
9:20 am
Discussion

 

9:30 am
Is Acetaminophen ALF a Good Model for ALF Management?
Roger Williams, CBE
9:50 am
Discussion
10:00 am
Break
Session IIB: Transplantation and Alternatives

Moderators: William M. Lee, MD and Marco L.A. Sivilotti, MD, MSc

10:20 am
Early Predictors of Long-Term Survival and Non-Survival
William Bernal, MD
10:40 am
Discussion
10:50 am
Liver Assist Technology: A Bridge Too Far?
Anne M. Larson, MD
11:10 am
Discussion
11:20 am
Human Hepatocyte Transplantation for Acute Liver Failure
Anil Dhawan, MD, FRCPCH
11:40 am
Discussion
Noon
Lunch
Session III: Preventing Acetaminophen Poisoning: Before and After the Event
Session IIIA: Defining the Safe Use of Acetaminophen
Moderators: Eric Lavonas, MD and Paul B. Watkins, MD
1:00 pm
Other Diagnostic and Prognostic Markers in Acetaminophen Toxicity
Marco L.A. Sivilotti, MD, MSc
1:20 am
Discussion
1:30 pm
Acetaminophen Protein Adducts
Laura James, MD
1:50 pm
Discussion
2:00 pm
Transaminase Elevations from Maximal Therapeutic Acetaminophen Dosing: Evidence from the “Up-and-Down” Study
Kennon Heard, MD
2:20 pm
Discussion
2:30 pm
Defining the Safe Daily Acetaminophen Dose: "Normal" Adults and Vulnerable Populations
Richard C. Dart, MD, PhD
2:50 pm
Discussion
3:00 pm
Break
Session IIIB: Strategies to Prevent Acetaminophen Poisoning
Moderators: Jody Green, PhD and Julia Wendon, MbChB, FRCP
3:15 pm
Presentation of Best Poster Awards
3:20 pm
Strategies for Harm Reduction: What Might Work?
Daniel S. Budnitz, MD, MPH, CAPT, USPHS
3:40 pm
Discussion
3:50 pm
Intravenous Acetaminophen (APAP): Special Safety Considerations
Barry H. Rumack, MD
4:10 pm
Discussion
4:20 pm
Opioid-Acetaminophen Combination Products: Should They Be Removed From the Market?
William M. Lee, MD
4:40 pm
Discussion and Wrap-up